VCM
AVLN

Vanguard Capital Management’s Avalyn Pharma AVLN Stock Holding History

Vanguard Capital Management’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4M Buy
+739,770
New +$21.3M ﹤0.01% 2342

Other funds holding AVLN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Capital Management's AVLN Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 739,770 shares worth $24.4M. The stake represents ﹤0.01% of the portfolio and ranks #2342 among its holdings.

38 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

  • Vanguard Capital Management held 739,770 shares of Avalyn Pharma worth $24.4M as of Q2 2026.
  • Avalyn Pharma was a new Vanguard Capital Management position in Q2 2026.
  • Avalyn Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2342 holding.
  • 38 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.